- Previous close:
- Day's range:
- $4.18 - $4.29
- Year's range:
- $3.06 - $5.05
- Net Income per Share:
- Price-to-Earnings ratio:
- 52-week Price Range:
- Average volume:
Company profile for Genfit S.A.
Genfit S.A. is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases. Founded in 1999 and headquartered in Loos, France, Genfit is dedicated to improving the lives of patients with chronic, life-threatening diseases.
Genfit’s primary drug candidate, Elafibranor, is currently in Phase 3 clinical trials to treat patients with primary biliary cholangitis. GNS561, another drug candidate, is in Phase 1b/2 trial to treat patients with cholangiocarcinoma. Additionally, the company is conducting Phase 1 trials for Nitazoxanide to treat acute-on-chronic liver failure.
To further its research, Genfit has partnered with a number of companies, such as Labcorp and Genoscience Pharma. Genfit signed a licensing agreement with Labcorp to commercialize the blood-based molecular diagnostic test NASHnext, while the agreement with Genoscience Pharma is to develop and commercialize the investigational treatment GNS561 for cholangiocarcinoma.
Committed to its mission, Genfit has an experienced executive team and board of directors, most notably its President and CEO, Pascal Prigent, who brings more than 25 years of pharmaceutical industry experience, including positions held at Sanofi S.A. and GlaxoSmithKline. In addition, Genfit has access to cutting-edge R&D capabilities and innovative technologies, such as the NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis.
Genfit is well-positioned to bring its innovative treatments and diagnostics to market. The company has established an international presence, with subsidiaries in the United States, Germany, and Belgium, as well as research operations in the United States and Canada. In pursuit of its vision of being an innovative research-driven biopharmaceutical company, Genfit has several ongoing clinical trials and has received the “Orphan Drug Designation” from the US Food and Drug Administration (FDA) for Elafibranor, a treatment for primary biliary cholangitis.
Genfit S.A. is dedicated to continuing to advance its pipeline of therapeutic and diagnostic candidates and to bring new treatments to market to advance the health of millions of people suffering from metabolic and liver-related diseases.
- Stock exchanges:
- 33 3 20 16 40 00